ATEA PHARMACEUTICALS INC (AVIR) Stock Price & Overview
NASDAQ:AVIR • US04683R1068
Current stock price
The current stock price of AVIR is 5.52 USD. Today AVIR is down by -3.33%. In the past month the price decreased by -0.9%. In the past year, price increased by 91%.
AVIR Key Statistics
- Market Cap
- 439.778M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.94
- Dividend Yield
- N/A
AVIR Stock Performance
AVIR Stock Chart
AVIR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to AVIR. When comparing the yearly performance of all stocks, AVIR is one of the better performing stocks in the market, outperforming 92.43% of all stocks.
AVIR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVIR. While AVIR has a great health rating, there are worries on its profitability.
AVIR Earnings
AVIR Forecast & Estimates
9 analysts have analysed AVIR and the average price target is 8.16 USD. This implies a price increase of 47.83% is expected in the next year compared to the current price of 5.52.
AVIR Groups
Sector & Classification
AVIR Financial Highlights
Over the last trailing twelve months AVIR reported a non-GAAP Earnings per Share(EPS) of -1.94. The EPS increased by 3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.23% | ||
| ROE | -57.49% | ||
| Debt/Equity | 0 |
AVIR Ownership
AVIR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.83 | 869.14B | ||
| JNJ | JOHNSON & JOHNSON | 17.83 | 555.642B | ||
| MRK | MERCK & CO. INC. | 22.11 | 289.223B | ||
| PFE | PFIZER INC | 9.14 | 156.544B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.38 | 120.728B | ||
| ZTS | ZOETIS INC | 16.71 | 51.606B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.443B | ||
| VTRS | VIATRIS INC | 5.91 | 17.315B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.49 | 11.825B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.651B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.206B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.087B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.11 | 4.929B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AVIR
Company Profile
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The firm has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
Company Info
IPO: 2020-10-30
ATEA PHARMACEUTICALS INC
225 Franklin Street, Suite 2100
Boston MASSACHUSETTS 02110 US
CEO: Jean-Pierre Sommadossi
Employees: 55
Phone: 18572048109
ATEA PHARMACEUTICALS INC / AVIR FAQ
What does AVIR do?
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The firm has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
What is the stock price of ATEA PHARMACEUTICALS INC today?
The current stock price of AVIR is 5.52 USD. The price decreased by -3.33% in the last trading session.
Does AVIR stock pay dividends?
AVIR does not pay a dividend.
What is the ChartMill rating of ATEA PHARMACEUTICALS INC stock?
AVIR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ATEA PHARMACEUTICALS INC (AVIR) based on its PE ratio?
ATEA PHARMACEUTICALS INC (AVIR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.94).
What is the next earnings date for AVIR stock?
ATEA PHARMACEUTICALS INC (AVIR) will report earnings on 2026-05-13.
What is the Short Interest ratio of ATEA PHARMACEUTICALS INC (AVIR) stock?
The outstanding short interest for ATEA PHARMACEUTICALS INC (AVIR) is 11% of its float.